The interlink between AMPK and Nrf2/HO-1 signalling and its potential in treatment of metabolic disease and cancer resurge in the new clinical perspective as a therapeutic option, particularly the cross-activation of these pathways that can control oxidative stress, inflammatory status, and cell metabolism, conferring protective actions against the progression of diseases and improving treatment responses42. Here, NFE2L2 is linked to metabolic disease.